Payment overview · 2025
General Payments
$2,346.20
129 reported records · 28 companies
Healthcare provider profile · identity verified
Christopher S Mcelroy, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · EVANS, GA · NPI 1346343134
Verified facts
What the public records show
CMS Open Payments records show Christopher S Mcelroy, M.D. received $2,346.20 in general payments during 2025 across 129 reported records.
Novo Nordisk Inc accounted for 18.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 42 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Linzess, Mounjaro, Ozempic, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Lumigan by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 213 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 178 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 227 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 227 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 192 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 201 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 102 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 452 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 128 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 350 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Paxlovid by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SOLIQUA 100/33 as an associated drug or biological on 43 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Soliqua 100-33 by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $432.61 | 18.4% | 24 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $201.58 | 8.6% | 15 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $183.65 | 7.8% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $177.40 | 7.6% | 9 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $170.46 | 7.3% | 7 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $149.95 | 6.4% | 16 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $136.87 | 5.8% | 8 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $134.98 | 5.8% | 8 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $81.92 | 3.5% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $77.68 | 3.3% | 5 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $49.20 | 2.1% | 3 | 2025 |
| Ionis Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $44.79 | 1.9% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $43.19 | 1.8% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $41.76 | 1.8% | 4 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $39.65 | 1.7% | 2 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $39.27 | 1.7% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $37.94 | 1.6% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $36.95 | 1.6% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $35.06 | 1.5% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $33.99 | 1.4% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $30.92 | 1.3% | 2 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $28.50 | 1.2% | 1 | 2025 |
| Mannkind Corporation | Unresolved — no canonical attribution shown | $27.45 | 1.2% | 1 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $25.73 | 1.1% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $24.01 | 1.0% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $23.10 | 1.0% | 1 | 2025 |
| Chiesi USA, Inc. | Unresolved — no canonical attribution shown | $19.81 | 0.8% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $17.78 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,281.66 | 127 |
| Education | $64.54 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $354.57 | 20 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $177.40 | 9 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $145.98 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $136.87 | 8 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $134.98 | 8 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $121.26 | 7 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $120.21 | 9 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $120.21 | 9 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $115.75 | 14 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $113.66 | 11 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $100.60 | 4 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $81.92 | 4 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $81.37 | 6 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $81.37 | 6 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $78.04 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $69.86 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $63.38 | 4 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $49.20 | 3 | 2025 |
Source payment records
|
|||||
| TRYNGOLZA Normalized: tryngolza |
Drug | Ionis Pharmaceuticals, Inc. | $44.79 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $43.19 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $43.19 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $41.76 | 4 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $39.65 | 2 | 2025 |
Source payment records
|
|||||
| REZUROCK Normalized: rezurock |
Drug | SANOFI-AVENTIS U.S. LLC | $39.27 | 1 | 2025 |
Source payment records
|
|||||
| Spectra WaveWriter Normalized: spectra wavewriter |
Device | Boston Scientific Corporation | $37.67 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $35.06 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $30.92 | 2 | 2025 |
Source payment records
|
|||||
| SAPIEN 3 Ultra RESILIA Normalized: sapien 3 ultra resilia |
Device | Edwards Lifesciences Corporation | $28.50 | 1 | 2025 |
Source payment records
|
|||||
| AFREZZA Normalized: afrezza |
Drug | Mannkind Corporation | $27.45 | 1 | 2025 |
Source payment records
|
|||||
| RECORLEV Normalized: recorlev |
Drug | Xeris Pharmaceuticals, Inc. | $24.01 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $23.10 | 1 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $19.96 | 1 | 2025 |
Source payment records
|
|||||
| JUXTAPID Normalized: juxtapid |
Drug | Chiesi USA, Inc. | $19.81 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $17.98 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $17.98 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $17.78 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $17.76 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $16.72 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $16.23 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $16.23 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $14.30 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $14.30 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 350 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 178 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 227 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 37 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 192 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 452 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 128 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 78 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
213 | 55 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
178 | 35 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
227 | 54 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
78 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
227 | 54 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
192 | 29 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
201 | 41 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
102 | 16 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
452 | 86 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
128 | 21 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
350 | 64 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
14 | 14 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | SOLIQUA 100/33 open payments reported associated product |
CMS Open Payments — General Payments 43 supporting records · 15 recipient NPIs · example record 1233224976 |
Soliqua 100-33 · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 1242 | 362 |
| Atorvastatin Calcium | Atorvastatin Calcium | 938 | 258 |
| Levothyroxine Sodium | Levothyroxine Sodium | 896 | 230 |
| Amlodipine Besylate | Amlodipine Besylate | 787 | 224 |
| Metformin Hcl Er | Metformin Hcl | 751 | 205 |
| Losartan Potassium | Losartan Potassium | 653 | 193 |
| Omeprazole | Omeprazole | 612 | 189 |
| Pravastatin Sodium | Pravastatin Sodium | 516 | 148 |
| Metoprolol Succinate | Metoprolol Succinate | 492 | 151 |
| Tramadol Hcl | Tramadol Hcl | 464 | 125 |
| Ozempic | Semaglutide | 452 | 86 |
| Lisinopril | Lisinopril | 398 | 129 |
| Pantoprazole Sodium | Pantoprazole Sodium | 378 | 106 |
| Metformin Hcl | Metformin Hcl | 367 | 115 |
| Eliquis | Apixaban | 350 | 64 |
| Trazodone Hcl | Trazodone Hcl | 322 | 81 |
| Ezetimibe | Ezetimibe | 320 | 100 |
| Meloxicam | Meloxicam | 314 | 98 |
| Gabapentin | Gabapentin | 313 | 104 |
| Alprazolam | Alprazolam | 308 | 83 |
| Furosemide | Furosemide | 294 | 95 |
| Tamsulosin Hcl | Tamsulosin Hcl | 289 | 95 |
| Prednisone | Prednisone | 284 | 181 |
| Pioglitazone Hcl | Pioglitazone Hcl | 281 | 78 |
| Telmisartan | Telmisartan | 259 | 77 |
| Bupropion Xl | Bupropion Hcl | 247 | 71 |
| Fluticasone Propionate | Fluticasone Propionate | 246 | 87 |
| Carvedilol | Carvedilol | 239 | 63 |
| Repatha Sureclick | Evolocumab | 235 | 42 |
| Potassium Chloride | Potassium Chloride | 234 | 67 |
| Jardiance | Empagliflozin | 227 | 54 |
| Famotidine | Famotidine | 226 | 57 |
| Zolpidem Tartrate | Zolpidem Tartrate | 222 | 53 |
| Simvastatin | Simvastatin | 221 | 58 |
| Synthroid | Levothyroxine Sodium | 213 | 55 |
| Sertraline Hcl | Sertraline Hcl | 209 | 52 |
| Montelukast Sodium | Montelukast Sodium | 205 | 60 |
| Clonazepam | Clonazepam | 204 | 50 |
| Trulicity | Dulaglutide | 201 | 41 |
| Fenofibrate | Fenofibrate | 196 | 56 |
| Mounjaro | Tirzepatide | 192 | 29 |
| Glimepiride | Glimepiride | 191 | 57 |
| Hydrochlorothiazide | Hydrochlorothiazide | 191 | 64 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 189 | 45 |
| Allopurinol | Allopurinol | 179 | 53 |
| Farxiga | Dapagliflozin Propanediol | 178 | 35 |
| Clopidogrel | Clopidogrel Bisulfate | 175 | 52 |
| Duloxetine Hcl | Duloxetine Hcl | 154 | 48 |
| Escitalopram Oxalate | Escitalopram Oxalate | 147 | 44 |
| Celecoxib | Celecoxib | 144 | 38 |
| Lorazepam | Lorazepam | 144 | 44 |
| Finasteride | Finasteride | 140 | 35 |
| Paroxetine Hcl | Paroxetine Hcl | 137 | 39 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 135 | 39 |
| Diazepam | Diazepam | 134 | 31 |
| Pregabalin | Pregabalin | 128 | 34 |
| Rybelsus | Semaglutide | 128 | 21 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 127 | 28 |
| Alendronate Sodium | Alendronate Sodium | 119 | 30 |
| Donepezil Hcl | Donepezil Hcl | 107 | 32 |
| Irbesartan | Irbesartan | 107 | 34 |
| Metoprolol Tartrate | Metoprolol Tartrate | 105 | 32 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 104 | 45 |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 104 | 21 |
| Entresto | Sacubitril/Valsartan | 102 | 16 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 102 | 28 |
| Fluoxetine Hcl | Fluoxetine Hcl | 100 | 33 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 96 | 26 |
| Diclofenac Sodium | Diclofenac Sodium | 95 | 42 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 93 | 24 |
| Hydralazine Hcl | Hydralazine Hcl | 93 | 22 |
| Valsartan | Valsartan | 93 | 30 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 92 | 23 |
| Tizanidine Hcl | Tizanidine Hcl | 92 | 35 |
| Citalopram Hbr | Citalopram Hydrobromide | 89 | 25 |
| Cefdinir | Cefdinir | 87 | 74 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 87 | 38 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 87 | 29 |
| Niacin Er | Niacin | 85 | 20 |
| Atenolol | Atenolol | 84 | 20 |
| Azithromycin | Azithromycin | 83 | 74 |
| Quetiapine Fumarate | Quetiapine Fumarate | 83 | 20 |
| Spironolactone | Spironolactone | 80 | 22 |
| Promethazine Hcl | Promethazine Hcl | 79 | 17 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 78 | 22 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 78 | 17 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 77 | 19 |
| Solifenacin Succinate | Solifenacin Succinate | 75 | 22 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 74 | 19 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 73 | 24 |
| Meclizine Hcl | Meclizine Hcl | 73 | 40 |
| Testosterone Cypionate | Testosterone Cypionate | 72 | 19 |
| Amitriptyline Hcl | Amitriptyline Hcl | 71 | 17 |
| Estradiol | Estradiol | 71 | 19 |
| Ondansetron Hcl | Ondansetron Hcl | 69 | 38 |
| Bupropion Hcl Sr | Bupropion Hcl | 66 | 14 |
| Ibuprofen | Ibuprofen | 66 | 30 |
| Methocarbamol | Methocarbamol | 65 | 22 |
| Ramipril | Ramipril | 65 | 17 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 59 | 16 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 58 | 13 |
| Praluent Pen | Alirocumab | 58 | 11 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 57 | 16 |
| Nebivolol Hcl | Nebivolol Hcl | 56 | 15 |
| Propranolol Hcl | Propranolol Hcl | 56 | 23 |
| Fenofibrate | Fenofibrate Nanocrystallized | 55 | 15 |
| Mirtazapine | Mirtazapine | 55 | 14 |
| Nitroglycerin | Nitroglycerin | 55 | 19 |
| Valacyclovir | Valacyclovir Hcl | 54 | 26 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 53 | 13 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 52 | 21 |
| Novolog Flexpen | Insulin Aspart | 50 | 15 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 49 | 15 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 48 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 48 | 17 |
| Azelastine Hcl | Azelastine Hcl | 46 | 15 |
| Hydrocortisone | Hydrocortisone | 46 | 12 |
| Warfarin Sodium | Warfarin Sodium | 46 | suppressed |
| Baclofen | Baclofen | 45 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 45 | 30 |
| Buspirone Hcl | Buspirone Hcl | 44 | suppressed |
| Topiramate | Topiramate | 44 | 12 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 44 | 20 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 44 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 43 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 42 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 42 | 18 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 41 | 40 |
| Ropinirole Hcl | Ropinirole Hcl | 41 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 40 | 16 |
| Eszopiclone | Eszopiclone | 40 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 40 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 40 | suppressed |
| Myrbetriq | Mirabegron | 40 | 14 |
| Temazepam | Temazepam | 40 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 39 | 35 |
| Naproxen | Naproxen | 39 | 13 |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 39 | suppressed |
| Calcitriol | Calcitriol | 38 | 38 |
| Dicyclomine Hcl | Dicyclomine Hcl | 38 | 17 |
| Doxazosin Mesylate | Doxazosin Mesylate | 38 | suppressed |
| Xarelto | Rivaroxaban | 38 | 11 |
| Linzess | Linaclotide | 37 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 37 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 35 | suppressed |
| Januvia | Sitagliptin Phosphate | 35 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 35 | 24 |
| Fluconazole | Fluconazole | 34 | 24 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 34 | 21 |
| Symbicort | Budesonide/Formoterol Fumarate | 34 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 33 | 11 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 31 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 31 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 31 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 30 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 30 | suppressed |
| Levetiracetam | Levetiracetam | 30 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 30 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 29 | 19 |
| Doxepin Hcl | Doxepin Hcl | 29 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 29 | 12 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 29 | 26 |
| Tresiba Flextouch U-100 | Insulin Degludec | 29 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 28 | suppressed |
| Carisoprodol | Carisoprodol | 27 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 27 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 27 | suppressed |
| Ondansetron Odt | Ondansetron | 27 | 17 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 26 | suppressed |
| Memantine Hcl | Memantine Hcl | 26 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 26 | suppressed |
| Primidone | Primidone | 26 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 25 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 24 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 24 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 24 | 16 |
| Spiriva Respimat | Tiotropium Bromide | 24 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 23 | 11 |
| Cephalexin | Cephalexin | 22 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 22 | suppressed |
| Humalog | Insulin Lispro | 22 | suppressed |
| Klor-Con M20 | Potassium Chloride | 22 | suppressed |
| Lansoprazole | Lansoprazole | 22 | suppressed |
| Amoxicillin | Amoxicillin | 21 | 16 |
| Propranolol Hcl Er | Propranolol Hcl | 21 | suppressed |
| Risperidone | Risperidone | 21 | suppressed |
| Chlorthalidone | Chlorthalidone | 20 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 20 | 18 |
| Enalapril Maleate | Enalapril Maleate | 20 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 20 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 19 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 19 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 19 | suppressed |
| Glipizide Er | Glipizide | 18 | suppressed |
| Insulin Lispro | Insulin Lispro | 18 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 18 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 18 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 18 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 18 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 17 | suppressed |
| Levofloxacin | Levofloxacin | 17 | 15 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 17 | 17 |
| Rizatriptan | Rizatriptan Benzoate | 17 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 16 | 12 |
| Digoxin | Digoxin | 16 | suppressed |
| Dutasteride | Dutasteride | 16 | suppressed |
| Sotalol | Sotalol Hcl | 16 | suppressed |
| Bumetanide | Bumetanide | 15 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 15 | suppressed |
| Letrozole | Letrozole | 15 | suppressed |
| Ranolazine Er | Ranolazine | 15 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 14 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 14 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 14 | suppressed |
| Nifedipine Er | Nifedipine | 14 | suppressed |
| Novolog | Insulin Aspart | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 14 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 14 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Loperamide | Loperamide Hcl | 13 | suppressed |
| Lumigan | Bimatoprost | 13 | suppressed |
| Methotrexate | Methotrexate Sodium | 13 | suppressed |
| Metronidazole | Metronidazole | 13 | 13 |
| Modafinil | Modafinil | 13 | suppressed |
| Vascepa | Icosapent Ethyl | 13 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 12 | suppressed |
| Invokamet Xr | Canagliflozin/Metformin Hcl | 12 | suppressed |
| Isosorbide Dinit-Hydralazine | Isosorbide Dinit/Hydralazine | 12 | suppressed |
| Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 12 | suppressed |
| Torsemide | Torsemide | 12 | suppressed |
| Xultophy 100-3.6 | Insulin Degludec/Liraglutide | 12 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 11 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 11 | 11 |
| Diltiazem 24hr Er | Diltiazem Hcl | 11 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Metaxalone | Metaxalone | 11 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 11 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 11 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,346.20 · 129 records | Novo Nordisk Inc | AFREZZA, AIRSUPRA, AREXVY, CAPLYTA, CAPVAXIVE, CREON, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, EVENITY, FANAPT, FARXIGA, GARDASIL 9, GEMTESA, JARDIANCE, JUXTAPID, Kerendia, Korlym, LEQVIO, LINZESS, MOUNJARO, NEXLETOL, NURTEC ODT, OTEZLA, Ozempic, PROLIA, RECORLEV, REPATHA, REZUROCK, Rybelsus, SAPIEN 3 Ultra RESILIA, SHINGRIX, Spectra WaveWriter, TRELEGY ELLIPTA, TRYNGOLZA, VERQUVO, VOQUEZNA, VRAYLAR, WATCHMAN FLX, Wegovy, XIFAXAN, ZEPBOUND | 16 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error